The production and sales of anti-tuberculosis drugs in ChinaReport as inadecuate

The production and sales of anti-tuberculosis drugs in China - Download this document for free, or read online. Document in PDF available to download.

Infectious Diseases of Poverty

, 5:88

First Online: 04 October 2016Received: 05 April 2016Accepted: 12 August 2016DOI: 10.1186-s40249-016-0184-z

Cite this article as: Huang, YM., Zhao, QP., Ren, QM. et al. Infect Dis Poverty 2016 5: 88. doi:10.1186-s40249-016-0184-z


BackgroundTuberculosis TB is a major infectious disease globally. Adequate and proper use of anti-TB drugs is essential for TB control. This study aims to study China’s production capacity and sales situation of anti-TB drugs, and to further discuss the potential for China to contribute to global TB control.

MethodsThe production data of anti-TB drugs in China from 2011 to 2013 and the sales data from 2010 to 2014 were extracted from Ministry of Industry and Information Technology database of China and IMS Health database, respectively. The number of drugs was standardized to the molecular level of the key components before calculating. All data were described and analyzed by Microsoft Excel.

ResultsFirst-line drugs were the majority in both sales 89.5 % and production 92.3 % of anti-TB drugs in China. The production of rifampicin held the majority share in active pharmaceutical ingredients APIs and finished products, whilst ethambutol and pyrazinamide were the top two sales in finished products. Fixed-dose combinations only held small percentages in total production and sales weight, though a slight increase was observed. The production and sales of streptomycin showed a tendency of decrease after 2012. The trends and proportion of different anti-TB drugs were similar in production and sales, however, the production weight was much larger than that of sales, especially for rifampicin and isoniazid.

ConclusionsFirst-line drugs were the predominant medicine produced and used in China. While the low production and sales of the second-line TB drugs and FDCs rose concerns for the treatment of multiple drug resistant TB. The redundant production amount, as well as the prompt influence of national policy on drug production and sales, indicated the potential for China to better contribute to global TB control.

KeywordsTuberculosis Drug First-line drug Second-line drug Rifampicin China Production Sales Abbreviations1,321ThProtionamide

APIsActive pharmaceutical ingredients



DOTSDirectly observed treatment, short-course


FDCsFixed-dose combination


MDR-TBMultiple drug resistant tuberculosis

MIITMinistry of industry and information technology


PASp-aminosalicylic acid







WHOWorld Health Organization

Electronic supplementary materialThe online version of this article doi:10.1186-s40249-016-0184-z contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Yang-Mu Huang - Qi-Peng Zhao - Qiao-Meng Ren - Dan-Lu Peng - Yan Guo


Related documents